News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis announces participation at upcoming conferences

March 14, 2022

Stockholm, Sweden, March 14, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that Nicklas Westerholm, CEO, will participate at the following upcoming conferences in March-May 2022:

Carnegie Virtual Nordic Healthcare Seminar
March 17, 2022: Presentation at 16:00-16:30 CET

Handelsbanken Triple H Event (virtual)
March 23, 2022

Kempen Life Sciences Conference, Amsterdam, The Netherlands
April 21, 2022

Redeye Theme: Orphan Drugs, Stockholm, Sweden
April 27, 2022

LSX World Congress, London, UK
May 11, 2022: Panel discussion 12:20-13:00 GMT ‘Multi-Jurisdictional Drug Development’

ABG Sundal Collier Life Science Summit, Stockholm, Sweden
May 18-19, 2022



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10